Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.
Risk and Volatility
Autolus Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500.
Insider and Institutional Ownership
72.8% of Autolus Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autolus Therapeutics | $75.39 million | 8.26 | -$287.53 million | ($1.06) | -2.21 |
| Nurix Therapeutics | $83.98 million | 32.46 | -$264.46 million | ($3.45) | -7.61 |
Nurix Therapeutics has higher revenue and earnings than Autolus Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for Autolus Therapeutics and Nurix Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autolus Therapeutics | 1 | 1 | 4 | 2 | 2.88 |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
Autolus Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 327.35%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 30.24%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Nurix Therapeutics.
Profitability
This table compares Autolus Therapeutics and Nurix Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autolus Therapeutics | -238.66% | -178.66% | -49.34% |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
Summary
Autolus Therapeutics beats Nurix Therapeutics on 10 of the 15 factors compared between the two stocks.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
